Management of Paronychia in HIV Patient on Dolutegravir and Tenofovir
Treat this paronychia as a standard infectious/inflammatory nail condition using conservative local measures, as neither dolutegravir nor tenofovir are known to cause paronychia—continue the HIV regimen without modification.
Key Clinical Context
The provided evidence focuses entirely on paronychia associated with EGFR inhibitors (cancer chemotherapy agents like cetuximab, panitumumab) and older HIV protease inhibitors (indinavir, lamivudine). Importantly, dolutegravir (an integrase inhibitor) and tenofovir (an NRTI) are not associated with paronychia as an adverse effect 1, 2. The historical reports of paronychia with antiretroviral therapy involved indinavir and lamivudine 3, 4, not the current regimen.
Management Approach
Grade Assessment First
Determine severity using CTCAE grading:
- Grade 1: Nail fold edema or erythema; disruption of cuticle
- Grade 2: Pain with discharge or nail plate separation; limits instrumental activities
- Grade 3: Requires surgical intervention or IV antibiotics; limits self-care
Treatment by Grade
Grade 1 Paronychia:
- Continue HIV medications unchanged
- Topical povidone-iodine 2% twice daily 5
- High-potency topical corticosteroids combined with topical antibiotics 5
- Warm water soaks 15 minutes, 3-4 times daily 6
- Reassess in 2 weeks
Grade 2 Paronychia:
- Continue HIV medications unchanged; monitor severity 5
- Obtain bacterial/viral/fungal cultures if infection suspected 5
- Topical povidone-iodine 2% twice daily PLUS topical corticosteroids and antibiotics 5
- Oral antibiotics (tetracyclines if not superinfected; quinolones [ciprofloxacin, levofloxacin, moxifloxacin] if superinfected) 7, 8
- Silver nitrate application weekly for granulation tissue 6, 7
- Podiatry referral for toenail involvement 6
- Reassess in 2 weeks
Grade 3 Paronychia:
- Continue HIV medications unchanged (do NOT interrupt antiretroviral therapy)
- Swab for culture and prescribe appropriate antibiotics based on resistance results 6
- Continue topical therapy as above
- Consider partial nail avulsion 5
- Dermatology/surgical referral 6, 7
Critical Preventive Measures
Educate patient on:
- Avoid cutting nails too short; trim straight across 5
- Minimize trauma and pressure to nails 7
- Daily emollient application to cuticles 5
- Wear comfortable, well-fitting shoes 5
- Keep hands/feet dry; wear cotton gloves under protective gloves 6
- Avoid nail biting 5
Special Considerations for HIV Patients
Immunosuppression increases infection risk:
- Up to 25% of paronychia cases have secondary bacterial or fungal superinfection 5
- Both gram-positive and gram-negative organisms implicated 5
- In HIV patients with low CD4 counts, consider broader antimicrobial coverage 9
- Terbinafine preferred over itraconazole if fungal infection suspected, due to fewer drug interactions with antiretrovirals 9
Drug Interaction Monitoring:
- Tenofovir has no significant interactions with topical or oral antibiotics used for paronychia 2
- Dolutegravir has no contraindications with standard paronychia treatments 1
- Continue HIV regimen without interruption to maintain viral suppression 10, 11, 12
Common Pitfalls to Avoid
- Do not discontinue or modify the HIV regimen for paronychia—this condition is unrelated to dolutegravir/tenofovir
- Do not assume drug-induced paronychia without evidence; treat as standard infectious/inflammatory process
- Do not delay culture if Grade 2 or higher—empiric antibiotics should be adjusted based on results
- Do not perform aggressive surgical intervention for Grade 1-2; conservative management is first-line 5
The evidence linking paronychia to antiretroviral therapy applies only to older agents (indinavir, lamivudine) 3, 4, not modern regimens. This patient's paronychia should be managed as a standard dermatologic condition while maintaining optimal HIV viral suppression with their current effective regimen 10, 13.